首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1448557

全球重組蛋白治療 CDMO 市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Recombinant Protein Therapeutics CDMO Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年02月01日 | 出版商:

Value Market Research | 英文 280 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球重組蛋白治療 CDMO 市場需求預計將從 2023 年的 212.3 億美元增至 2032 年的近 693.7 億美元，2024-2032 年研究期間CAGR為 14.06%。

重組蛋白療法 CDMO（合約開發和製造組織）涉及透過基因工程提供治療性蛋白質開發和生產服務的公司。這些組織在推動生物製藥、確保重組蛋白藥物生產流程高效且合規方面發揮重要作用。

市場動態

重組蛋白療法 CDMO 市場受到慢性病盛行率日益上升等因素的影響，推動了對生物製藥解決方案的需求。由於專業服務提供者提供的成本效益和專業知識，將製造流程外包給合約開發和製造組織 (CDMO) 越來越受歡迎。生物技術的進步，包括基因治療和個人化醫療，有助於市場的擴張。此外，重組蛋白製造的複雜性和對專業設施的需求促使生物製藥公司尋求外部 CDMO 專業知識。對生物製藥開發的監管支持和不斷成長的重組蛋白藥物管道進一步推動了市場的成長，為 CDMO 提供者創造了機會，以滿足生物製藥行業不斷變化的需求。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球重組蛋白治療 cdmo 市場的每個細分市場進行了包容性評估。重組蛋白治療 cdmo 產業的成長和趨勢為本研究提供了整體方法。

市場區隔

重組蛋白治療 cdmo 市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略家確定相應產品或服務的目標人口統計數據以及即將到來的機會。

按類型

生長激素
干擾素
疫苗
免疫刺激劑
其他

按來源

哺乳動物系統
微生物系統
其他

按指示

腫瘤學
傳染性疾病
免疫系統疾病
代謝紊亂
血液系統疾病
其他

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲重組蛋白治療 CDMO 市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。重組蛋白治療 CDMO 市場的主要參與者包括 Richter-Helm BioLogics、Lonza、Catalent, Inc、FUJIFILM Diosynth Biotechnologies、WuXi Biologics、Curia Global, Inc.、Batavia Biosciences BV、HALIX BV、BIOVIAN、Enzene Biosciences Ltd。包括對競爭競爭格局的整體看法，包括各種策略發展，例如關鍵併購、未來能力、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：重組蛋白治療 CDMO 公司的競爭格局

重組蛋白治療Cdmo市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

公司股份分析
市場集中度
Richter-Helm BioLogics

公司簡介
公司收入
產品
最近的發展

Lonza

公司簡介
公司收入
產品
最近的發展

Catalent Inc

公司簡介
公司收入
產品
最近的發展

FUJIFILM Diosynth Biotechnologies

公司簡介
公司收入
產品
最近的發展

WuXi Biologics

公司簡介
公司收入
產品
最近的發展

Curia Global Inc.

公司簡介
公司收入
產品
最近的發展

Batavia Biosciences BV

公司簡介
公司收入
產品
最近的發展

HALIX BV

公司簡介
公司收入
產品
最近的發展

BIOVIAN

公司簡介
公司收入
產品
最近的發展

Enzene Biosciences Ltd

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112113789

The global demand for Recombinant Protein Therapeutics CDMO Market is presumed to reach the market size of nearly USD 69.37 BN by 2032 from USD 21.23 BN in 2023 with a CAGR of 14.06% under the study period 2024 - 2032.

Recombinant protein therapeutics CDMO (Contract Development and Manufacturing Organization) involves companies providing services for the development and production of therapeutic proteins through genetic engineering. These organizations are important in advancing biopharmaceuticals, ensuring efficient and compliant production processes for recombinant protein-based drugs.

MARKET DYNAMICS

The recombinant protein therapeutics CDMO market is influenced by factors such as the increasing prevalence of chronic diseases, driving the demand for biopharmaceutical solutions. Outsourcing of manufacturing processes to Contract Development and Manufacturing Organizations (CDMOs) is gaining traction due to cost-effectiveness and expertise offered by specialized service providers. Advancements in biotechnology, including gene therapy and personalized medicine, contribute to the market's expansion. Additionally, the complexity of manufacturing recombinant proteins and the need for specialized facilities drive biopharmaceutical companies to seek external CDMO expertise. Regulatory support for biopharmaceutical development and the growing pipeline of recombinant protein drugs further fuel the market's growth, creating opportunities for CDMO providers to cater to the evolving needs of the biopharmaceutical industry.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of recombinant protein therapeutics cdmo. The growth and trends of recombinant protein therapeutics cdmo industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the recombinant protein therapeutics cdmo market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Growth Hormones
Interferons
Vaccines
Immunostimulating Agents
Others

By Source

Mammalian Systems
Microbial Systems
Others

By Indication

Oncology
Infectious Diseases
Immunological Disorders
Metabolic Disorders
Haematological Disorders
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Recombinant Protein Therapeutics CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Recombinant Protein Therapeutics CDMO market include Richter-Helm BioLogics, Lonza, Catalent, Inc, FUJIFILM Diosynth Biotechnologies, WuXi Biologics, Curia Global, Inc., Batavia Biosciences B.V., HALIX B.V., BIOVIAN, Enzene Biosciences Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . RECOMBINANT PROTEIN THERAPEUTICS CDMO - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Source
- 3.7.3 Market Attractiveness Analysis By Indication
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET ANALYSIS BY TYPE

5.1 Overview by Type
5.2 Historical and Forecast Data
5.3 Analysis by Type
5.4 Growth Hormones Historic and Forecast Sales by Regions
5.5 Interferons Historic and Forecast Sales by Regions
5.6 Vaccines Historic and Forecast Sales by Regions
5.7 Immunostimulating Agents Historic and Forecast Sales by Regions
5.8 Others Historic and Forecast Sales by Regions

6 . GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET ANALYSIS BY SOURCE

6.1 Overview by Source
6.2 Historical and Forecast Data
6.3 Analysis by Source
6.4 Mammalian Systems Historic and Forecast Sales by Regions
6.5 Microbial Systems Historic and Forecast Sales by Regions
6.6 Others Historic and Forecast Sales by Regions

7 . GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET ANALYSIS BY INDICATION

7.1 Overview by Indication
7.2 Historical and Forecast Data
7.3 Analysis by Indication
7.4 Oncology Historic and Forecast Sales by Regions
7.5 Infectious Diseases Historic and Forecast Sales by Regions
7.6 Immunological Disorders Historic and Forecast Sales by Regions
7.7 Metabolic Disorders Historic and Forecast Sales by Regions
7.8 Haematological Disorders Historic and Forecast Sales by Regions
7.9 Others Historic and Forecast Sales by Regions

8 . GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE RECOMBINANT PROTEIN THERAPEUTICS CDMO COMPANIES

9.1. Recombinant Protein Therapeutics Cdmo Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF RECOMBINANT PROTEIN THERAPEUTICS CDMO INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. Richter-Helm BioLogics
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Lonza
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Catalent Inc
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. FUJIFILM Diosynth Biotechnologies
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. WuXi Biologics
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Curia Global Inc.
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. Batavia Biosciences B.V.
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. HALIX B.V.
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. BIOVIAN
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Enzene Biosciences Ltd
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments